Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?

Area of Science:

• Pediatric Hematology
• Immunology

Background:

• Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
• Standard treatment guidelines for ITP have evolved, particularly concerning therapies with potential risks.

Observation:

• A 5-year-old boy presented with severe isolated thrombocytopenia (platelet count 2×10(9)/L).
• The patient exhibited clinical signs of bleeding, including epistaxis and oral mucosal bleeding.
• The child was Rh-positive, with normal hemoglobin levels.

Findings:

• The use of anti-D immunoglobulin in Rh-positive individuals with ITP is contraindicated.
• The 2010 Food and Drug Administration (FDA) issued a black-box warning regarding the risks associated with anti-D immunoglobulin therapy in this population.
• This warning highlights the potential for serious adverse events, including hemolytic anemia and death.

Implications:

• Clinicians should avoid anti-D immunoglobulin as an initial therapy for ITP in Rh-positive children.
• Alternative evidence-based treatments for pediatric ITP should be prioritized.
• Adherence to FDA warnings is crucial for patient safety in pediatric hematology.